Clinical Trial

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Name: A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome — clinical trial record (NCT07569081)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATLAS

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.

Protocol Amendment History 1 change

notable Enrollment reduced: 192 -> 136 participants 2026-06-02

Trial Details

NCT Number	NCT07569081
Lead Sponsor	GlaxoSmithKline
Conditions	VEXAS Syndrome
Enrollment	136 participants
Start Date	2026-08-05
Primary Completion	2028-12-06 (estimated)
Study Completion	2031-06-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-01